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Abstract
Background: Doxorubicin is one of the most effective anti-cancer drugs but its use is limited by cumulative cardiotoxicity
that restricts lifetime dose. Redox damage is one of the most accepted mechanisms of toxicity, but not fully substantiated.
Moreover doxorubicin is not an efficient redox cycling compound due to its low redox potential. Here we used genomic and
chemical systems approaches in vivo to investigate the mechanisms of doxorubicin cardiotoxicity, and specifically test the
hypothesis of redox cycling mediated cardiotoxicity.
Methodology/Principal Findings: Mice were treated with an acute dose of either doxorubicin (DOX) (15 mg/kg) or 2,3-
dimethoxy-1,4-naphthoquinone (DMNQ) (25 mg/kg). DMNQ is a more efficient redox cycling agent than DOX but unlike
DOX has limited ability to inhibit gene transcription and DNA replication. This allowed specific testing of the redox
hypothesis for cardiotoxicity. An acute dose was used to avoid pathophysiological effects in the genomic analysis. However
similar data were obtained with a chronic model, but are not specifically presented. All data are deposited in the Gene
Expression Omnibus (GEO). Pathway and biochemical analysis of cardiac global gene transcription and mRNA translation
data derived at time points from 5 min after an acute exposure in vivo showed a pronounced effect on electron transport
chain activity. This led to loss of ATP, increased AMPK expression, mitochondrial genome amplification and activation of
caspase 3. No data gathered with either compound indicated general redox damage, though site specific redox damage in
mitochondria cannot be entirely discounted.
Conclusions/Significance: These data indicate the major mechanism of doxorubicin cardiotoxicity is via damage or
inhibition of the electron transport chain and not general redox stress. There is a rapid response at transcriptional and
translational level of many of the genes coding for proteins of the electron transport chain complexes. Still though ATP loss
occurs with activation caspase 3 and these events probably account for the heart damage.
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Introduction
Doxorubicin (DOX), is one of the most widely used anticancer
drugs for solid tumours, but its use is compromised by lifetime dose
related cardiotoxicity [1]. Furthermore therapy related cardiotox-
icity has become more apparent as chemotherapy becomes more
successful in lengthening patient survival [2]. DOX cardiotoxicity
is reproduced in several species including mice, indicating a non-
species specific mechanism of toxicity [3].
Several hypotheses have been reported for the mechanism of
cardiotoxicity [4]. However the most commonly described
mechanism is through redox action [5]. DOX has a redox
potential of 2328 mV, that while not ideal for redox activity [6],
does allow it to be reduced slowly by a number of redox centres in
the cell [7,8]. Additionally DOX has an affinity for cardiolipin [9],
found in the inner mitochondrial membrane that can concentrate
DOX in the mitochondria where it can be reduced by complex I
of the electron transport chain (ETC). Overexpression of catalase
decreases DOX toxicity supporting the redox hypothesis[10].
Other data though suggest the mechanism is mutifactorial, in
particular involving mitochondria [11]. Inhibition of the ETC
could happen through the local formation of ROS on complex I
causing damage [12]. Alternatively the interaction of DOX with
cardiolipin could lead to inhibition of the ETC as cardiolipin is
required for normal ETC activity [13]. Furthermore, DOX can
induce p53 as a result of its genotoxic properties and this in turn
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can lead to inhibition of the mTOR pathway that can affect
mRNA translation[14–15]. Co-administration of redox inhibitors
and ROS scavengers does not ameliorate the cardiotoxicity in the
clinic also supporting the involvement of mechanisms other than,
or in addition to, redox activity[16,17].
Metabolism of DOX in the heart occurs by carbonyl reductase
to form doxrubicinol [18] and overexpression of carbonyl
reductase increases cardiotoxicity in vivo [19]. Doxorubicinol can
cause the release of iron from the cytoplasmic aconitase causing
the iron free aconitase to behave like iron regulatory protein (IRP)
[20]. IRP causes increased levels of transferrin by mRNA
stabilisation, and decreased levels of ferritin by reduced mRNA
translation[21]. This may lead to increased free iron that could
lead to Fenton chemistry occurring. Conversely, DOX may also
inhibit IRP [20,22] preventing binding to the iron response
element (IRE). These studies indicate the effect of DOX on iron
regulation in cardiomyocytes is complex. Support for an important
role of altered iron homeostasis is indicated by co-administration
of the iron chelating agent dexrazoxane. Dexrazoxane is partially
chemoprotective for DOX cardiotoxicity and is the only approved
drug for co-administration with DOX [23]. Downstream of these
events loss of cardiomyocytes occurs. In vitro apoptosis is
responsible but a role for apoptosis in vivo has not been conclusively
demonstrated [4].
Here we used two novel approaches to add clarity to the
mechanisms by which DOX initiates cardiotoxicity. First a
chemically related quinone 2,3-dimethoxy-1,4-naphthoquinone
(DMNQ) [24] was used as a comparator. DMNQ has an optimal
redox potential of 2183 mV for redox activity (thereby replicating
the favored mechanistic hypothesis for DOX), and causes
cardiotoxicity, but unlike DOX has only limited inhibitory effects
on DNA replication and transcription. Second a global genomics
approach at both transcriptional and translational levels was
utilised to elucidate the biochemical pathways affected by both
DOX and DMNQ. We utilised an acute dose over a short time
course to avoid the complication of pathological change. We have
previously published on the kinetic profiles of DMNQ[24]that
reaches a Cmax within 10 minutes in heart after i.p. administration.
For doxorubicin the kinetics are different. Johansen [25] has
shown in the mouse after i.p. administration of a 12 mg/kg dose of
doxorubicin that maximum tissue levels are not reached until two
hours. To provide some level of equivalence in this study we
therefore conducted the time course of analysis for doxorubicin
from 30 minutes and DMNQ from 5 minutes.
Results
Many hypotheses for DOX cardiotoxicity involve an element of
redox cycling. In order to investigate the redox hypothesis further
a biologically less complex, but redox active, quinone (DMNQ)
was utilised. This allowed the redox properties of DOX to be
differentiated. DMNQ has similar electro chemical characteristics
to DOX but is much less able to inhibit DNA synthesis (Figure 1A).
The pharmacokinetics and metabolism of DMNQ have been
previously established and these data were used to design the dose
and time schedules [24].
Characterisation of cardiac damage
The model was evaluated using established biomarkers in
addition to TCap mRNA, a novel biomarker identified in this
study. Both DOX and DMNQ increased the heart/bodyweight
(BW) ratio over a time period of 120 hr (Figure 1B). Similarly a
dose response of increased heart/BW ratio was observed for 2.5 to
25 mg/kg at 120 hr after dosing (Figure 1C). A significant increase
in the MB form of CK was measured from 5 min that continued
to increase to 1 hr for both DOX and DMNQ (Figure 1D).
Increased CK-MB was confirmed by native PAGE analysis to
separate the three CK isoforms (Figure 1E and F). Plasma
Troponin (TpI) was measured and a rapid increase observed after
DMNQ (single 25 mg/kg) maximal at the first time point
measured (30 min.) that decreased at 12 hr after dosing. The
response with DOX was less acute but more prolonged
(Figure 1G). Global transcriptional profiling showed the mRNA
of the Titin-Cap (TCap) gene tracked our other markers of cardiac
dysfunction very effectively. Our data indicate that expression of
this gene in cardiac tissue increased with damage and is indicative
of the observed pathophysiology (Figure 1H). Collectively these
data indicate that rapid damage to the cardiac muscle is occurring
after a single dose of either DOX or DMNQ.
Transcriptional analysis
Pathway analysis of transcription data indicated the functionally
associated set of genes most differentially regulated in the cardiac
muscle were those of the mitochondrial ETC (Figure 2A).
Increased ETC gene transcription was seen, particularly for
DMNQ, at the early time points after a single acute dose. After
30 min the increased transcription had resolved somewhat,
corresponding with majority clearance of the DMNQ [24].
Changes in gene transcription were less marked following acute
DOX that may reflect inhibition of transcription associated with
DOX pharmacological action but not DMNQ. Several genes were
selected for verification using qRT-PCR from each of the
complexes and these are shown in Figure 2 for DOX (Figure 2B)
and DMNQ (Figure 2C). Complex genes verified by qRT-PCR
are indicated by grey arrows (Figure 2).
Translational analysis
DOX inhibits gene transcription so we examined if regulation of
mRNA translation was altered. Cardiac mRNA with attached
ribosomes was fractionated on a sucrose gradient, the UV profile
monitored during gradient unloading (Figure 3A) and fractions
pooled according to 40S and b-actin expression (Figure 3A).The
40S mRNA level defined the monosomal (non-translated) fraction
and b-actin mRNA level the polysomal (actively translated) fraction.
Microarray analysis yielded similar pathways to those seen with the
transcriptional analysis, in particular ETC, for both DOX and
DMNQ (Figure 3B). However DOX caused a greater increase in
mRNA levels through alteration of translation than DMNQ.
Biochemical analysis of ETC complex activity
The activity of each ETC complex was analysed independently in
cardiac muscle taken from animals over a time course following
acute DOX or DMNQ. For complexes I to III activity decreased
over the time course from 10 mins to 24 hr (Figure 4, A to C). In
contrast activity of complexes IV and V were increased (Figure 4 D
and E). To determine if any increase in mitochondrial mass had
occurred the activity of citrate synthase was determined (Figure 4F).
For citrate synthase a significant, increase across the time course of
similar overall fold change to the increase in activity of complex IV
was observed.
Effects on cellular biochemistry
Effects on the ETC would most likely first manifest as changes
in the ATP/ADP/AMP ratios in the cardiomyocytes. After acute
DOX or DMNQ there was a rapid fall in cardiomyocyte ATP
(80–90%) within 10 mins post dosing. This was followed by
recovery from 2 hr. DOX also induced falls in ADP and AMP
Doxorubicin Cardiotoxicity
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levels that similarly recovered by 24 hr. DMNQ had a similar
effect on ADP levels but showed an initial rise in AMP levels after
dosing (Figure 5A). Overall, following a single dose of either DOX
or DMNQ the AMP:ATP ratio increased whereas ATP:ADP ratio
decreased. We measured mitochondrial amplification by qRT-
PCR of 10 of the 13 protein coding mitochondrial genes and
found an average amplification across the whole of the genome
following either DOX (Figure 5B) or DMNQ (Figure 5C)
treatment. The degree of mitochondrial genome amplification
correlated well with the increase in citrate synthase activity
(Figure 4F) suggesting both could have been due to increased
mitochondrial mass. AMPK is activated by increased AMP:ATP
ratio and seven genes that code for the AMPK complex (Prkaa1,
Prkag3, Prkag1, Prkag2, Prkaa2, Prkab1 and Prkab2) were increased
over the time course from 10 to 120 min following acute DOX or
DMNQ (Figure 5D and E).
Quinones are capable of causing the formation of methemo-
globin by oxidizing the Fe2+ of hemoglobin in the process of
forming the semiquinone. We measured the formation of
methemoglobin after single acute doses of DOX or DMNQ.
DMNQ led to methemoglobin formation at 10 mins. the point of
maximum plasma concentration [24], but DOX did not
(Figure 5F).
To determine if intrinsic apoptosis was occurring downstream of
the mitochondrial changes we measured levels of activated caspase
3, an executioner caspase [26]. Caspase 3 was increased with acute
DOX and DMNQ up to 50 fold for DOX by 30 min post dose
(Figure 5G).
Finally the effect of DOX on mitochondrial membrane
potential and the cytoskeleton was assessed in HL-1 cells. In
untreated cells there was diffuse a-actinin staining (Figure 6A) and
the cells were stained green indicating a normal mitochondrial
potential (Figure 6D). After exposure to DOX at 1 mM (Figure 6B
and E) or 5 mM (Figure 6C and F) for 24 hours the a-actinin had
condensed (Figure 6B and C) and there was a marked loss of
mitochondrial potential (Figure 6E and F). At 5 mM there was
substantial cell death (Figure 6C and F).
Discussion
Many hypotheses have been advanced for DOX cardiotoxicity
including redox cycling, inhibition of the ETC, iron release,
activation of the mTOR pathway and induction of apoptosis
(reviewed in [4]). Most studies that have led to these hypotheses
have been carried out either in vitro or chronic dosed in vivo models
that have limitations for genomic analysis. For the in vitro studies
compared to those in vivo there are environmental differences for
example oxygen tension and media composition that can result in
non-specific alteration of gene expression or cell damage that may
not occur in vivo. For chronic models there are the problems of
overlying pathophysiological change that can alter the initiating
insult. For these reasons we used an acute DOX model to identify
events initiating the cardiomyopathy. A similar approach has been
utilized previously [27]. Moreover the multiple biological and
pharmacological properties of DOX can complicate the associa-
tion of chemical property and biological effect. To address this we
utilized DMNQ, a redox active quinone with a much weaker effect
on DNA/protein synthesis compared to DOX (Figure 1A). We
had already generated data on the toxicokinetics and metabolism
of DMNQ [24] and therefore first demonstrated here that DMNQ
causes a similar cardiotoxicity to DOX (Figure 1). We then used
DMNQ to discern effects of DOX associated with inhibition of
DNA replication and transcription. As DOX inhibits gene
transcription directly by DNA adduct formation and probably
through activation of mTOR [15] we hypothesized, and
discovered here, that DOX had a limited effect on overall gene
transcription compared to DMNQ. Additionally therefore we
profiled mRNA translation through the use of mRNA density
fractionation followed by global microarray analysis (Figure 3).
Pathway analysis for transcriptional and mRNA translational
data showed for both DOX and DMNQ the most significantly
altered genes were associated with oxidative phosphorylation, the
ETC and actin cytoskeleton. Gene expression changes associated
with these pathways became apparent from 5 min (DMNQ) or
30 min (DOX) post dosing and were prolonged (to 120 hr). Such
persistent alterations in gene expression following DOX have been
described previously [28]. This was of particular interest with
DMNQ as the pathways remained deregulated after the
compound would have been eliminated. This is concordant with
metabonomics data for DMNQ in the liver that shows reduced
glucose and increased lactate at 96 hr suggesting an ongoing
deregulation of oxidative metabolism [24]. This would lead to
cumulative effects in chronic dosing. Absent was any indication of
global redox stress and so we discounted this as the mechanism of
toxicity and focused on the ETC. In vitro it is still quite possible that
redox activity is a mechanism of toxicity where oxygen tensions
are higher than in vivo [29,30].
Biochemical analysis of each ETC complex showed that
complexes I to III were reduced in activity (Figure 4) while those
of complexes IV and V were increased (Figure 4 D and E) in
accordance with previous analyses [12]. There was an approxi-
mate two fold increase in mitochondrial mass measured by citrate
synthase activity (Figure 4F) that could account for the increased
activity of complexes IV and V, but not for decreased activity of
the former complexes. A possible explanation is that DOX or
DMNQ was taking electrons from complex I and transporting
them not to oxygen but to cytochrome c thereby short-circuiting
the electron transport chain[31](Figure 7). DOX is extensively
bound to cardiolipin and a pool of cytochrome c is also bound to
cardiolipin in the membrane. The cytochrome c/cardiolipin
complex has a greater negative redox potential than unbound
cytochrome c that would diminish its ability to oxidise the
semiquinone, but still its close proximity could still favor the
reaction [32]. We cannot however completely discount the
possibility of a local redox reaction on complex I or III. In either
scenario inhibition of the ETC would reduce the ATP levels, as
Figure 1. Determination of Cardiac Damage. A) Effect of DOX (filled circles) and DMNQ (open circles) on incorporation of 3H-thymidine/3H-
leucine (open circles) in the mouse cardiac cell line HL-1. Incorporation was measured after 24 hr exposure to the indicated concentration. DOX
significantly different from DMNQ p=0.003 two way ANOVA. B) Heart: body weight ratio change with time after a single acute dose of DOX (15 mg/
kg, filled circle) or DMNQ (25 mg/kg, open circle), or vehicle (triangle). C) Heart:body weight ratio following a dose response 120 hrs post dosing
(DOX filled circles and DMNQ open circles). D) CK-MB activity determined from plasma following DOX (filled circles) or DMNQ (open circles). E and F)
Native protein gels DOX (E) and DMNQ (F)probed for CK. Coomassie blue stain indicated equal protein loading. G) Troponin I activity determined
from plasma following DOX (filled circles) or DMNQ (open circles) using an ELISA assay kit. H) TCap mRNA levels from the microarray data over time
after acute DOX (filled circles) or DMNQ (open circles). In all graphs mean and SD are plotted. For DOX in D the SDs are very small and hidden behind
the points. B,D and G: Statistical analyses performed using a one way ANOVA to time 0 with Dunnetts post-hoc t-test. * = p,0.05, except D where all
points were significant.
doi:10.1371/journal.pone.0012733.g001
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observed (Figure 5A). Decreased ATP leads to an activation of
AMPK; we observed increased expression of the genes of the
AMPK complex (Figures 5E and F) [33]. AMPK activity is also
increased in response to decreased ATP to protect against
apoptosis, explaining the decrease in caspase 3 activity through
the time course (Figure 5G) [34]. Therefore the increased AMPK
expression we observed could be an indication that the
cardiomyocytes were trying to avoid apoptosis. Furthermore,
reduced ATP could lead to mitochondrial damage and increased
mitochondrial genome copy number or mitochondrial mass. The
increase in mitochondrial genome copy number (Figure 5, C and
D) appears to indicate the former but this can be partially
accounted for by increased mitochondrial replication suggesting
the overall response is a combination of both increased replication
and genome amplification (Figure 4F). Formation of methemo-
globin induced by DMNQ, particularly at the 10 min time point,
indicated that DMNQ might be causing acute cardiac injury by
hypoxia. Methemoglobin probably explains why PCA analysis of
the whole transcriptome data plotted the 10 min. time point
separated from the other time points (Supplemental Figure S1).
Gene expression changes regulated by the hypoxia inducible
factor (HIF-1a) and nuclear respiratory factor (NRF-1) may
indicate if hypoxia occurred with DMNQ as a result of
methemoglobin formation. Genes with HIF-1a binding sites were
not altered in expression but several of those regulated by NRF-1
were. NRF-1 is an important transcription factor controlling
transcription of complexes of the ETC [35]. NRF-1 null mice do
not survive more than 3.5 to 6.5 days post coitum [36]. Both DOX
and DMNQ activated NRF-1 (Supplemental Figure S2). This
increase in NRF-1 correlated with increased expression of genes
with a binding site for this transcription factor (Supplemental
Figure S3). Many of the Cox genes that form part of Complex IV
have a binding site for NRF-1 and were increased in expression
particularly with DMNQ. The activation of the NRF-1 genes with
DOX and DMNQ, and not those regulated by HIF-1a, suggests a
specific response of factors of the ETC and not a general response
to methemoglobin formation.
Our data, and that previously published, leads us to the following
hypothesis for DOX cardiotoxicity that is summarized in Figure 7.
While the redox potential of DOX (2328 mv) is not ideal for redox
cycling because the redox potential is too low to allow for efficient
reduction by NADH:ubiquinone reductase[6,7] there is clear
electron spin resonance evidence that DOX is reduced by complex
I forming the semiquinone in isolated mitochondrial preparations
[37] and it seems entirely feasible that this also occurs in vivo. In vitro
there is also clear evidence that the superoxide radial is sub
sequentially formed completing the redox cycle [38]. In vivo the
completion of the redox cycle may not occur. The use of cellular
and subcellular preparations in vitro does not necessarily mimic the
conditions in vivo particularly in respect of oxygen tension. Most cells
are cultured in conditions of 5% CO2 and air and will result in an
oxygen partial pressure in the cells of approximately 150 mmHg
[29]. In contrast within heart mitochondria the oxygen partial
pressure is much lower. Data from Mik et al [39] indicates a linear
relationship between oxygen tension and atmospheric concentra-
tion in rats with a partial pressure of about 60 mmHg at 20% O2
and a mitochondrial oxygen tension in the heart of 35 mmHg;
considerably lower than the in vitro conditions. The overall effect of
reduced oxygen tension on the redox reactions in vivo will be to
decrease the rate of superoxide generation. Therefore while redox
reactions may occur in vivo the amount of superoxide formed will
likely be considerably less than is likely to be formed in vitro.
Combined with effective cellular systems in vivo to deal with
superoxide and its derivatives, and the rather non specific cellular
interactions by which superoxide causes cell death, redox cycling in
vivo does not appear totally convincing as a mechanism for DOX
induced cardiotoxicity. This hypothesis is supported by clinical
trials that have failed to show a benefit of antioxidants suggesting
that formation of active oxygen species is not the predominant route
of toxicity [16,17]. In this study using genomics we failed to find any
evidence of redox stress at either the level of transcription or mRNA
translation.
While a redox signature was not seen in the genomic analysis
signatures of some common gene expression pathways were
quickly activated, prominent amongst them was the ETC
pathway. This is a pathway commonly found induced during
genomic systems analysis, and often a non-specific indicator of
cellular stress. It’s very rapid activation here though caused us to
investigate further whether this might be a cause rather than
consequence of the toxicity. Further support for investigating this
pathway was gained through the use of DMNQ. As with DOX,
for DMNQ in vivo no evidence for redox cycling was observed
from the genomic analysis, but similarly to DOX a rapid induction
of genes of the ETC occurred. For both DOX and DMNQ
biochemical analysis indicated a loss of activity in complex I
(Figure 4) commensurate with a main compound interaction with
this complex, and additionally a slight increase in Complex IV
activity similar to that observed previously in DOX treated rats
[40]. Previous published data of rotenone inhibition of reversed
ETC activity with DOX in sub mitochondrial particles showed
that DOX is reduced on complex I proximal to the site of
rotenone inhibition [37] supporting this hypothesis. It is interesting
to speculate that while redox reactions may occur more readily in
vitro due to the higher oxygen tension inhibition of the ETC is
likely to be less effective in vitro as a mechanism of toxicity. This is
due to cells in vitro generally being cultured in a high glucose
concentration and utilizing glycolysis for the generation of ATP
[41]. Thus it may be that while DOX could cause toxicity in vitro
through redox reactions in vivo inhibition of the ETC is probably
more important.
If the oxygen tension in vivo makes redox reactions less likely
than in vitro there is still the question of what happens to the
semiquinone once produced from reduction of the quinone by
complex I. Previous studies have shown that menadione and
DOX, once one electron reduced by complex I, can transfer the
electron further down the ETC possibly to cytochrome c in a
process known as electron shunting [31,42,43]. Our own work
with DMNQ has shown that DMNQ is able to stimulate oxygen
consumption in rotenone inhibited sub mitochondrial particles,
and that this effect is cyanide sensitive indicating a similar ability
(data not shown). We suggest that this mechanism is more likely to
occur in vivo rather than production of superoxide.
Figure 2. Effect of DOX and DMNQ on gene transcription in the heart in vivo after an acute dose over time. Microarray transcriptional
analysis following acute DOX or DMNQ. A) Transcriptional gene clusters associated with each of the ETC complexes as indicated. Each cluster
represents a two time courses with DOX on the left and DMNQ on the right. Genes significantly altered (p#0.05) in expression in at least one time
point were included. Magenta is increased expression and blue decreased expression with the densest colour representing a 2.5 log fold (5.6 fold)
change from time matched control. Grey arrows show those genes verified by qRT-PCR in panels B and C. B) and C) qRT-PCR of ETC associated gene
expression changes following DOX (B) and DMNQ (C).
doi:10.1371/journal.pone.0012733.g002
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Whether redox cycling or electron shunting occurs the net result
will be the same, a loss of ATP (Figure 5) as there is a much greater
dependency on oxidative phosphorylation to generate ATP in vivo
than there is in vitro. We observed this through in the
mitochondrial gene amplification, probably indicating mitochon-
drial fission and activation of the AMP sensitive complex AMPK
which has many cellular functions associated with restoring the
ATP balance in the cell [33,44]. Ultimately this process can lead to
a loss of mitochondrial membrane potential (Figure 6) and release
of cytochrome c with activation of caspase 3 (Figure 5) and
apoptosis (Figure 7). There is broad agreement in the literature
that the loss of cardiomyocytes following DOX administration
occurs by apoptosis [45], and that the subsequent stress on the
remaining cells could lead to cardiomyopathy at prolonged periods
of time after the DOX exposure. This has recently been elegantly
shown in juvenile mice exposed to DOX that were susceptible to
stress induced myocardial injury as adults [46].
If this hypothesis is correct then the most important question is, can
the chemical structure of DOX be altered to give fewer detrimental
cardiac effects? One possible method would be to co-administer
DOX with an AMPK activator to try and maintain ATP. Another
possible way forward would be to add groups that can reduce the
DOX redox potential without affecting the ability of the molecule to
inhibit topoisomerase II, or adduct DNA. Mitoxanthrone represents
one such analog that attempts to achieve this. It has a more negative
redox potential than DOX (2450 mV) and has no cardiotoxicity as a
result. Unfortunately its pharmacological activity is not as favorable as
that for DOX. The cannaboid derivative HU-331 has also been
proposed to be more pharmacologically potent than DOX and its
structure suggests a low redox potential [47]. While not ideal as
chemotherapeutic agents these molecules indicate the route forward
to a better DOX and support the mechanism of cardiotoxicity
proposed from the data in this study.
Materials and Methods
Synthesis of DMNQ and animal treatment
DMNQ was synthesised according to the method of Gant et al.
(1988) [48]. Dosing solutions were prepared and animal treatment
performed as described in Parry et al. (2009) [24], with the
exception of DOX, which was dissolved in 0.9% w/v saline. All
procedures are licensed under UK Home Office project licence
80/2048. For dosing DOX was used at 15 mg/kg and DMNQ at
25 mg/kg.
De novo protein and DNA synthesis
De novo protein and DNA synthesis was assessed in HL-1 cells
by measuring the incorporation of L-[4, 5-3H]-leucine or [6-3H] –
thymidine, respectively. HL-1 cells were obtained from Dr.
William Claycomb (LSU Health Sciences, New Orleans, USA)
and cultured according to Claycomb et al. 1998 [49]. Cells were
seeded into a 96 well plate (56104/well) after treatment (0.1–
10 mM DOX or DMNQ dissolved in 0.1% DMSO), media was
removed and replaced with complete media containing labelled
leucine or thymidine to a final concentration of 1uCi/well and
incubated at 37uC for 2 hours. Following this media was removed
and replaced with 200 ml of 10% (w/v) trichloroacetic acid and
again incubated at 37uC for 10 minutes before being aspirated,
followed by the addition of 200 ml of 1 M NaOH to each well.
The plate was incubated at 37uC overnight. One hundred and fifty
microlitres of the resulting solution was assessed for leucine or
thymidine incorporation by scintillation counting. Results were
expressed as a ratio of the thymidine/leucine incorporation
normalised to the untreated control.
Creatine kinase
The creatine kinase MB assay (Randox CK-1296) was used, all
reagents were used as directed by the manufacturer and mixed
with 40 ml of plasma and incubated at 25uC for 10 minutes before
being transferred to a cuvette (Sarstedt, 1064645 mm). Absor-
bance at 340 nm was recorded (A1) and again 5 minutes later (A2).
CK-MB activity was then calculated as described by the
manufacturer.
Creatine kinase isozyme analysis
Plasma samples containing 35 mg protein were mixed with 66
loading buffer (50% (v/v) glycerol, Tris/glycine running buffer
(250 mM Tris-base, 1.9 M glycine, pH 8.6), 0.25% (w/v) xylene
cyanol) and separated on 7.5% polyacrylamide (PAGE) gel, with a
3.5% stacking gel in Tris/glycine running buffer at 150 V at 4uC
and transferred onto nitrocellulose membranes (Hybond-ECL,
Amersham Biosciences) by semi dry blotting. After blocking in 5%
(v/v) non-fat milk in TBST (10 mM Tris, 150 mM NaCl, 0.1%
(v/v) Tween 20) for 2 hours, the membranes were incubated with
a specific antibody to CK-MB diluted in 5% (v/v) non-fat milk in
TBST (1:200) (sc-28898, Santa Cruz Biotechnology) for 2 hours at
RT. Membranes were washed three times in TBST for 5 minutes
each, and incubated with anti-rabbit IgG antibody (Cell Signalling
Technology) conjugated to horseradish peroxidise in 5% (v/v)
non-fat milk in TBST (1:1000) for 1 hour at RT and then washed
three times with TBST for 5 minutes each. Bands were visualised
by chemiluminescence (GE Healthcare), for 2 minutes without
shaking. The membranes were wrapped in plastic wrap and placed
in a film cassette in the dark and exposed to x-ray film (ECL
hyperfilm, GE Healthcare) for 30 seconds to 2 minutes and
developed. Band intensities were measured by computerized
image analysis software. To assess equal protein loading, gels were
stained with Coomassie Brilliant Blue R-250 (Bio-Rad) for 30
minutes while shaking and destained with 40% (v/v) methanol
(Fisher Scientific) and 10% (v/v) glacial acetic acid (Fisher
Scientific) solution for 1 hour, with changes to solution every 10
minutes. An image of the gel was then obtained by scanning.
Troponin I
The mouse cardiac troponin-I (cTnI) ELISA kit (2010-1-HSP
Life Diagnostics) was used to determine cTnI levels in circulating
plasma. All reagents were used as supplied and directed by the
manufacturer.
RNA extraction
To each tissue sample (100 mg) 1 ml Tri Reagent was added
and homogenised and incubated at RT for 5 minutes before
Figure 3. Effect of DOX and DMNQ on mRNA translation in the heart in vivo after an acute dose with time. Microarray translational
analysis after acute DOX or DMNQ. A) UV profile of heart lysate illustrating separation of mRNA and northern blot of b-actin to show the position of
the polysomes. B) Translated gene clusters associated with each of the ETC complexes as indicated. Each cluster represents two time courses with
DOX on the left and DMNQ on the right. All genes that were significantly altered (P#0.05) in expression in at least one time point were included.
Magenta is increased expression and blue decreased expression the densest colour representing a 2.5 log fold change (5.6 fold) from time matched
control. Grey arrows indicate those genes in complex IV regulated by NRF-1.
doi:10.1371/journal.pone.0012733.g003
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Figure 4. Mitochondrial complex activity in the heart in vivo after an acute dose of DOX or DMNQ. Single acute dose; DOX (Black) and
DMNQ (Grey). Complex I to V activity is shown in Figures A to E respectively, the activity of complexes II and III was inferred by subtractions of the
activity of the relevant inhibited sample from the total complex II-III assay respectively. F) Mitochondrial mass measured by citrate synthase activity.
All time points compared to time 0 using a one way ANOVA with Dunnetts post hoc t-test. On all plots except F all points significantly different from
time 0 except those indicated by X. For plot F * indicates significantly different from time 0 (one way ANOVA with Dunnetts post hoc t-test; p,0.05.
doi:10.1371/journal.pone.0012733.g004
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200 ml of 1-bromo-3-chloro-propane was added to each sample.
Lysates were shaken for 20 seconds and vortexed before
incubation for 3 minutes at RT. Followed by centrifugation at
13,000 rpm for 15 minutes at 4uC; this separates the lysate into
two aqueous phases. The upper aqueous phase was transferred to
a new tube and 600 ml of isopropanol added and incubated at RT
for 10 minutes, before centrifugation at 13,000 rpm for 10 minutes
at 4uC. The supernatant was removed and the resulting pellet was
washed twice in 1 ml 75% (v/v) ethanol and centrifuged at
13,000 rpm for 10 minutes at 4uC. The supernatant was removed
and pellets dried and suspended in 20 ml water. Extracted RNA
was quantified using the NanoDrop ND-1000 UV spectropho-
tometer (Nanodrop technologies) and stored at 280uC.
DNA extraction
DNA was extracted using a Qiagen kit (QIAamp H DNA
micro). All reagents were used as supplied and DNA extracted
from 10 mg heart tissue.
Transcriptional analysis
Two color microarrays with reverse labelling were carried out using
a full genome mouse oligo array (70 mers), using exon centred probes
(Mouse Exonic Evidence Based Oligonucleotide set (http://www.bio.
davidson.edu/projects/GCAT/protocols/mouse/Oligator_MEEBO_
Data_Sheet.pdf). Invitrogen), a total of 39,000 oligos were covered
including spliced variants, positive, negative and doped controls. These
probes were printed onto aldehyde slides (Genetix) using a Stanford
type microarray spotter in house [50,51]. Total RNA was diluted to
7 mg before the addition of 8 mg oligo dT23N2 and 10nmol random
pentadecamers and incubated at 95uC for 5 minutes and 70uC for 10
minutes. Samples were then reverse transcribed with Superscript III
(Invitrogen) and aadUTP was incorporated. Any remaining RNA was
hydrolysed and samples neutralised by the addition of 1 M HEPES
(pH 7.0). The resultant cDNA was cleaned up using Microcon YM-30
filters (Millipore), prior to conjugation with relevant Alexa fluorophores
(Molecular Probes, Invitrogen). Any unbound dye was removed
using the Qiagen PCR purification kit (Qiagen) according to the
manufacturer’s instructions. Dye incorporation was assessed using a
NanoDrop ND-1000 UV (NanoDrop technologies) spectrophotome-
ter. 2x enhanced hybridisation buffer (Genesiphere) and 4 mg Yeast
tRNA (Invitrogen) was added to each sample, samples were denatured
prior to loading on to the microarray and allowed to hybridize
overnight at 42uC. Following hybridization slides were washed three
times in 1XSSC/0.03%, room temp., 10 min/0.2XSSC room temp.,
5 min./0.05%SSC room temp., 5 min. Slides were scanned using an
Axon 4200A scanner with GenePix 6.0 software. For each analysis 5
biological replicates were used with two technical replicates (reverse
labeling).
Quantitative Real-Time Reverse Transcriptase PCR (qRT-
PCR)
mRNA expression of selected genes were determined by qRT-
PCR as described [52]using SYBRH green mastermix on an ABI
PRISMH 7700 RT-PCR machine. Separate genes were run in
parallel. In brief 100 ng RNA was diluted in 4.5 ml water mixed
with 0.5 ml 90OD random hexamers and heated to 95uC for 5
minutes and snap cooled on ice and reversed transcribed using
8.25 ml of RT master mix (5xPCR buffer, 100 mM dATP,
100 mM dCTP, 100 mM dGTP, 100 mM dTTP, and 0.1 M
DTT), 0.25 ml of RNasin (Promega), and 0.5 ml of Superscript III
(Invitrogen) and incubated at 50uC for 1 hour then 70uC for 15
minutes before storage at 220uC. Primers for qRT–PCR were
designed to cross exon-intron boundaries to eliminate the
detection of any contaminating genomic DNA using Primer
ExpressH software v2.0 (Applied Biosystems) and are shown in
Table 1. Concentrations for each primer pair were optimised from
50 to 900 nM and the concentrations that gave the lowest Ct
values used in the assay.
Translational Profiling Using Microarrays: Sample
Preparation
50 mg of heart tissue perfused with 100 mg/ml cycloheximide
was homogenised in 250 ml ice cold lysis buffer (15 mM Tris-HCl
pH 8, 300 mM NaCl, 15 mM MgCl2, 1% (v/v) Triton X-100,
100 mg/ml cycloheximide, 1 mg/ml heparin, 80 U/ml RNAsin).
Samples were incubated on ice for 15 minutes followed by
centrifugation at 12,000 rpm for 5 minutes at 4uC. 300 mg protein
was loaded directly onto each sucrose gradient. Three animals
were used with separate preparations of monosome and polysomes
per time point and individual microarray analysis.
Translational Profiling Using Microarrays: Sucrose
Gradient Preparation and Centrifugation
8 ml of 65% (w/v) sucrose solution in lysis buffer (15 mM Tris-
HCl pH 7.5, 300 mM NaCl, 15 mM MgCl2, 100 mg/ml cyclo-
heximide, 1 mg/ml heparin, 1 mM DTT) and 8 ml lysis buffer
was prepared and cooled to 4uC. A linear 10–65% sucrose
gradient was prepared using a gradient station machine in
Beckman ultra-clear centrifuge tubes (14695 mm). The sample
lysates (above) were loaded directly onto the top of a gradient and
centrifuged at 200,000 g for 2 hours at 4uC [53]. After
centrifugation gradients were fractionated by upward displace-
ment into 1 ml aliquots. The absorbance at 254 nm was
monitored throughout; samples were collected into 1 ml TRIH.
Translational Profiling Using Microarrays: Purification of
RNA and labelling
Equal amounts of RNA from appropriate fractions (i.e.
polysomes or monosomes) were pooled and precipitated with
163 M NaOAc pH 5.0 and 36100% (v/v) ice cold ethanol at
220uC overnight. Following centrifugation at 13,000 rpm for 15
minutes at 4uC, the resultant pellets were washed twice in 1 ml of
75% (v/v) ethanol by centrifugation at 13,000 rpm for 5 minutes
at 4uC each and suspended in 10 ml of water. A direct labelling
method was used with Cy3- or Cy5-dUTPs (GE Healthcare). Cy3
and Cy5 have a wavelength of 532 and 647 nm, respectively. 10 ml
Figure 5. Mitochondrial associated biochemical effects following a single acute dose of DOX or DMNQ in vivo in cardiac tissue. A)
ATP/AMP/ADP levels measured using internally controlled HPLC; DOX (filled circles) or DMNQ (open circles) * = p,0.05 one way ANOVA with
Dunnetts post hoc t-test. B and C) Mitochondrial genome amplification was measured by qRT-PCR of 10 of the mitochondrial genes in cardiac tissue.
From left to right the bars show the level of ND1, CytB, Cox2, ND2, ND3, ND5, ND6, Cox3, Cox1, and ATP6 as a log 2 fold change relative to control
following treatment with DOX (B) or DMNQ (C), line is the average change at each time point. Expression AMPK complex genes; DOX (D) or DMNQ (E).
Bars represent log 2 fold changes relative to control and the line is the average change for all of the complexes at each time point. Left to right:
Prkaa1, Prkag3, Prkag1, Prkag2, Prkaa2, Prkab1 and Prkab2. F) Methemoglobin levels in the blood DOX (Black bars) or DMNQ (Grey bars) * = p,0.05
one way ANOVA with Dunnetts post hoc t-test.G) Caspase 3 activation DOX (Black bars) or DMNQ (Grey bars). Values represent fold change over
control. Statistics were performed using one way ANOVA with Dunnetts post hoc t-test. For all points p,0.001.
doi:10.1371/journal.pone.0012733.g005
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Figure 6. Effect of DOX on mitochondrial membrane potential and sarcomeric a-actinin expression in HL-1 cells. HL-1 cells were
treated for 24 hours with 0.1% DMSO (A and D), 1 or 5 mm DOX (B–C and E–F). Mitochondrial membrane potential was assessed using mitotracker (A,
C and E) and sarcomeric a-actinin by antibody (B, D and F). Green fluorescence shows mitochondrial membrane potential and red the expression of
a-actinin. Where overlay of expression occurred the fluorescence appears orange.
doi:10.1371/journal.pone.0012733.g006
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of the purified RNA sample (above) was incubated at 95uC for 3
minutes and snap cooled on ice for 1 minute. 1.0 ml of oligo
dT23N2 (8 mg/ml) was added to each sample and incubated at
70uC for 8 minutes. 6.5 ml of direct labelling mix (dATP 0.5 mM,
dGTP 0.5 mM, dCTP 0.5 mM, dTTP 0.2 mM, 1xfirst strand
buffer (Invitrogen) and DTT 0.01 M) and 1 ml of Superscript III
(Invitrogen), 0.5 ml of RNAsin (Promega) and 2 ml of the
appropriate Cy dye were added to each sample and incubate at
50uC for 2 hours. Any remaining RNA was hydrolysed by the
addition of 20.5 ml water, 1 ml of 0.5 M EDTA, 1 ml of 10% (w/v)
SDS and 3 ml of 3 M NaOH to each sample and incubated at
70uC for 10 minutes and neutralised by the addition of 10 ml of
1 M Tris-HCL (pH 7.5) and 3 ml of 2 M HCL (Fisher). The
resultant cDNA was purified and suspended in 20 ml water.
Labelling efficiency was measured and equal amounts of labelled
cDNA (Cy-3 and Cy-5) were combined. Samples were made up to
a volume of 40 ml with water, 1 ml of Yeast tRNA (4 mg/ml,
Invitrogen) and 40 ml of 26 enhanced cDNA hybridisation buffer
(Genisphere) were added to each sample and incubated at 42uC
for 30 minutes. Hybridization was conducted using a humidified
chamber (Genetix Ltd, Hampshire, UK) overnight at 42uC.
Translational Profiling Using Microarrays: Northern
Blotting with Fractionated RNA
A 1% denaturing agarose gel with 18% (v/v) formaldehyde in
1xMOPS (0.2 M MOPS (pH 7.0), 80 mM NaOAc, 10 mM
EDTA) was prepared by melting 80 mg agarose in 57.7 ml of
water prior to the addition of 8 ml of 10xMOPS and 14.3 ml of
formaldehyde and cast. Once set, the gel was submerged in
1xMOPS in an electrophoresis tank. An equal volume of each
fraction (5.5 ml) was mixed 1:1 with denaturing buffer (70% (v/v)
deionised formamide, 25% (v/v) formaldehyde, 1xMOPS and
30 mg ethidium bromide) and incubated at 95uC for 15 minutes
and snap cooled on ice. 2 ml RNA loading buffer (50% (v/v)
deionised formamide, 1 mM EDTA, 0.25% (w/v) bromophenol
blue and 0.25% (w/v) xylene cyanol) was added to each sample,
prior to samples being loaded into the gel and separated overnight
at 20 V. Gel images were obtained with a UVP BioImaging
System (UVP, Cambridge, UK). RNA was transferred from the
gel onto a positively charged nylon membrane (Genetix, New
Milton, UK) by capillary transfer overnight in 3xSSC. The
membrane was UV cross-linked at 120 mJ/cm2 for 60 seconds.
Probes for b-actin were labelled with 32P using E.coli Klenow
Figure 7. Schematic of the proposed mechanism of DOX toxicity resulting from inhibition of ATP production from the ETC. The
figure shows the hypothesis of electron shunting from Complex I by doxorubicin leading to a loss of ATP and activation of caspase 3.
doi:10.1371/journal.pone.0012733.g007
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fragment, incorporation was measured by scintillation counting.
Membranes were hybridised overnight at 42uC with 16106 dpm/
ml probe.
Mitochondrial complex activities
Cardiac tissue samples were prepared according to Gellerich
et al [54]. In brief 200 mg heart tissue was homogenised in 250 ml
PBS and centrifuged at 4uC for 1 minute at 6000 rpm; the
resultant supernatant was stored at 280uC prior to assay. Protein
concentrations of samples were determined using the Bradford
assay. Measurement of all complexes except complex V is
described by Barrientos (2002) [55] and assays were scaled to a
96 well plate format. Citrate synthase activity was measured
according to the method of Gellerich et al. (2004) [54].
Mitochondrial complex activities: Complex I Activity
A 1:1 dilution of sample with 0.5% (v/v) triton X100 in PBS
were prepared and incubated on ice for 1 hour. 3 ml of the
resulting lysate was added to each well of a 96 flat bottomed plate
(Greiner bio-one), this equated to ,130 ug protein/well. Each
sample was measured in triplicate reactions. 4 ml of 1 mM
rotenone (in 100% (v/v) ethanol) was added to inhibit any
complex I activity. Reaction buffer (Table 2) was added to each
well. Absorbance of each 96 well plate was measured at 340 nm
every 9 seconds for 10 minutes at 37uC on a SPECTRAmax
PLUS 384 spectrophotometer (Molecular Devices).
Mitochondrial complex activities: Complex II-III Activity
20 mg protein was placed in each well of a 96 well plate each
sample was measured in triplicate. 18 ml of 0.5% (v/v) tween 20 in
PBS was added to each well containing biological material. To one
set of triplicate samples 3 ml of 1 mM antimycin-A (in 100% (v/v)
ethanol) was added. In another set of triplicate samples 5 ml of
500 mM TTFA (in 100% (v/v) ethanol) was added. Reaction
buffer (Table 2) was added to each well. Absorbance of each 96
well plate was measured at 550 nm every 9 seconds for 10 minutes
at 37uC on a SPECTRAmax PLUS 384 spectrophotometer
(Molecular Devices).
Table 1. Primers used for qRT-PCR.
Gene Forward Primer Reverse Primer
Ndufs8 CTGCCCTGTTGATGCCATT TGTACAGCAACTCCTCGTGTGTCT
Ndufa8 GCCAACTCTGGAAGAGCTGAAA GTGATGGGCGGCAGCTT
Atp8a2 TCTGCGACAACCGGATCAG CCTAATCTGCTCATACAGGAATCG
Atp6v1e GATTGACCAGGAGGCCTACCT TTGCGATCCCCATTATAGATCTC
Atp5h ACGCCAGGTTGGCTAGTCTGT GGCCACATTGGCCCTGTAG
Atp5g1 CCACCAAGGCACTGCTCATT CAGGAGGGAGGCAGACACA
Ndufs1 CCTAACCTCTAAGCCTTATGCCTTTA GCATCCATTACATCAATGGACTCT
Cox6c CATTGTGGCCCTGGGAGTT TTCTGCATACGCCTTCTTTCTTG
mt-CytB TTATCGCGGCCCTAGCAA TTTAATCCTGTTGGGTTGTTTGATC
Atp5o AGCTTGTAAGGCCCCCTGTT AGAGTACAGGGCGGTTGCAT
Ndufs2 CGGAAATGTGACCCTCACATC GGGCCTGCAGATAGGTCTTGT
Tcap GAAGAGGGATGCTCCTTGCA GCTGTACCACCGCCTGACA
TBP GCGGTCGCGTCATTTTCT CGGAACTCGCACAAAGCA
Prkaa2 CGTGTGACATTATGGCTGAAGTGTA TACTCGAAGATGGTATGCATTCACTA
Prkab1 GTCATGCTGAACCACCTCTATGC TGTACCGGTGTGTTGCACTGA
Prkab2 GAGCCCAATCATGTTATGCTGAA TTGCGCTAAGGACCATCACA
Prkaa1 AACAGGACCAGAAAGTTATCTAGTGTGA TGACACTTTGTTTGGCGTTTG
Prkag3 GACGTGCTGTATGGCAAAGTTG TCAAGTCCAGAGGCATTTTCCT
Prkag1 CAGCCACCTGCCAAGCA ACAGACCTGGACGGGTGAGTT
Prkag2 TTGAAGGTGTTGTGAAGTGCAAT GATGGACCTCAGCTCTTACTATTCTGT
mtDNA copy number
ND-1 CGGGCCCCCTTCGAC GGCCGGCTGCGTATTCT
ND-2 CACGATCAACTGAAGCAGCAA ACGATGGCCAGGAGGATAATT
ND-3 TGTACTCAGAAAAAGCAAATCCATATG AATAATAGAAATGTAATTGCTACCAAGAAAAA
ND-5 CGGACGAACAGACGCAAATA TAAAATGAATCCGATGTCTCCGA
ND-6 TTGATGGTTTGGGAGATTGGTT TGCCGCTACCCCAATCC
mt-CytB TTATCGCGGCCCTAGCAA TAATCCTGTTGGGTTGTTTGATCC
Cox2 CATCCCAGGCCGACTAAATC TTTCAGAGCATTGGCCATAGAA
Cox3 CAGGAT TCTTCTGAGCGTTCTATCA AATTCC TGTTGGAGGTCAGCA
Cox1 GAAGAGACAGTGTTTCATGTGGTGT TCCTGGGCCTTTCAGGAATA
mt-ATP6 TGTGGAAGGAAGTGGGCAA CCACTATGAGCTGGAGCCGT
Each primer pair was optimised for concentration before use. The concentrations giving the lowest Ct value were used.
doi:10.1371/journal.pone.0012733.t001
Doxorubicin Cardiotoxicity
PLoS ONE | www.plosone.org 14 September 2010 | Volume 5 | Issue 9 | e12733
Mitochondrial complex activities: Complex IV Activity
10 mg protein was placed in each well of a 96 well plate, each
sample was measured in triplicate and each triplicate was duplicated,
to the duplicate samples 25 ml of 8 mM sodium azide was added to
inhibit any complex IV activity. Reaction mix (Table 2) was added to
each well. Absorbance was measured at 550 nm every 9 seconds for
10 minutes at 37uC on a SPECTRAmax PLUS 384 spectropho-
tometer (Molecular Devices).
Mitochondrial complex activities: Complex V Activity
Samples were homogenised in 250 mM sucrose, 2 mM EGTA,
and 20 mM Tris pH 7.4 at 4uC. 15 mg protein was added into each
well of a 96 flat bottomed plate. Each sample was measured in
triplicate and each triplicate set was further duplicated. To the
duplicate samples 3 ml of 1 mM oligomycin (in 100% (v/v) ethanol)
was added to inhibit complex V activity. Reaction buffer (Table 1)
was added to each well. Absorbance was measured at 340 nm every
9 seconds for 5 minutes at 37uC on a SPECTRAmax PLUS 384
spectrophotometer, this constitutes the pre-read plate. Following
this 75 ml of 10 mM MgATP was added per well and again the
absorbance was measured at 340 nm every 9 seconds for 10
minutes.
Citrate Synthase Activity
100 ug protein was mixed 1:1 with 0.5% (v/v) triton X 100 in PBS
and incubated on ice for 1 hour. 3 ml of the resulting lysate was added
to each well of a 96 well plate, reaction buffer (per well, containing
25 ml of 0.4 mg/ml DTNB (dissolved in 1 M Tris-HCl pH 8.1),
7.5 ml of 10 mg/ml acetyl CoA (dissolved in acidified water pH 5.0)
and 165 ml water) was added to each well. Absorbance was measured
at 412 nm every 9 seconds for 3 minutes on a SPECTRAmax PLUS
384 spectrophotometer, this constitutes the pre read plate. Following
this 12.5 ml of 0.5 mM oxaloacetic acid was added per well and the
plate was again read at 412 nm every 9 seconds for 5 minutes. Prior
to calculation of activity the pre-read plate Vmax was subtracted from
the post oxaloacetic acid plate.
Mitochondrial complex activities: Calculation of activity
Complex and citrate synthase activity was calculated for each
sample when the change in absorbance against time was linear. This
change was taken as the maximum rate of reaction (Vmax) where the
regression value is equal to 1. The absorbance of the inhibited
samples was subtracted from the corresponding non-inhibited
samples to obtain the Vmax of complex activity in each sample.
Data was normalized to the amount of protein in each sample and
expressed as DAbs/min(Vmax)/ug protein. The inverse Vmax/ug
protein was plotted to avoid confusion over the change in activity.
Measurement of ATP/ADP/AMP Activity by HPLC
50 mg of heart tissue was homogenised in 1 ml of 10% (v/v)
perchloric acid. Samples were centrifuged at 10,000 rpm for 15
minutes at 4uC. Internal standards were added and the resulting
supernatant neutralised with 1 M KOH and subjected to HPLC
[56]. HPLC was performed on a BDS-Hypersil 25064.6 mm C18
5 mm column using a Transgenomic HPLC Analyser. Buffer A
was 83.3 mM triethylammonium phosphate (TEAP) pH 6.0 and
Buffer B was HPLC grade methanol. The flow rate was set at
1 ml/min. The injection volume was 10 mL. ATP/ADP/AMP
was monitored at 206 nm and the amount of ATP/ADP/AMP in
each sample determined by calibration of the system with
standards of known concentration and the data analysed with
reference to the standards and expressed as mM/g tissue.
Caspase 3
Caspase 3 activity was measured using a colorimetric assay
according to the manufacturer’s instructions (Clontech). For this
assay 10 mg of heart tissue was homogenized in the kit lysis buffer.
mtDNA copy number
Genomic DNA (100 ng) was isolated using QIAampH DNA
micro kit (Qiagen) and was subjected to amplication with SYBRH
green mastermix on an ABI PRISMH 7700 RT-PCR machine as
described above. Primers were designed using Primer Design
software. Data was normalized to that of a nuclear encoded gene.
Relative quantification was performed with the comparative cycle
threshold method (Applied Biosystems, User Bulletin No. 2, 1997).
Methemoglobin assay
Methemoglobin levels were determined in whole blood according
to the method of Anders and Chung 1984 [57]. In duplicate 25 ml of
blood was mixed with 2 mls of water and incubated at RT. Following
incubation 25 ml of 30 g/L hydrogen peroxide was added to one of
the samples (A1) and 10 ml of 50 g/L sodium nitrite to the other (A2).
8 ml PBS (pH 6.6) was added to all samples and 1 ml of each sample
placed into a cuvette (Sarstedt, 1064645 mm). 5 ml of the control
sample was further diluted with an additional 5 ml PBS (pH 6.6) and
1 ml placed in a cuvette (Sarstedt, 1064645 mm); this sample was
used as a blank. The absorbance at 405 nm was recorded. Results
were calculated as follows: methemoglobin %= (A1/A2)6100.
Imaging
HL-1 cells were simultaneously stained with 0. 8 mM Hoechst
and 100 nMMitrotracker deep red (Invitrogen) diluted in claycomb
media for 1 hour at 37uC. Following incubation cells were washed
twice with PBS, before being fixed and permeabilized with 3.7%
Table 2. Reaction buffers used for mitochondrial complex activity measurements.
Reaction buffer per well
Complex I Complex II-III Complex IV Complex V
In 200 ml: 25 mM K2HPO4 titrate
to pH 7.4 with KH2PO4, 12.5 ul
of 50 mg/ml fatty acid free BSA,
7.5 ml of 5 mM NADH, 12.5 ml of
40 mM sodium azide, 3.75 ml of
5 mM coenzyme Q10 (in 100%
(v/v) ethanol) and 13.75 ml of
ddH2O, pre-warmed to 37uC
In 150 ml: 166 mM K2HPO4 titrate
to pH 7.4 with KH2PO4, 12.5 ml of
40 mM sodium azide, 3 ml of 0.5 M
succinate, 3 ml of rotenone (1 mM),
25 ml of 0.1% (w/v) BSA and 31.5 ml
of 10.4 mg/ml cytochrome c,
pre-warmed to 37uC
In 62.5 ml: 40 mM K2HPO4 titrate
to pH 6.5 with KH2PO4, 1 M sucrose
and 4 mg/ml fatty acid free BSA,
18 ml of 6.25 mM lautyl maltoside
and 10 mM reduced cytochrome C
in a volume of 205 ml
Per well: 20 ml of 0.5 M Tris-HCL (pH 8.0),
2 ml of 0.5 M MgCl2, 20 ml of 10 mM
NADH, 12.5 ml of 100 mM PEP, 20 ml of
50 mg/ml fatty acid free BSA, 4 ml of
1 mM rotenone, 3 ml of 1 mM antimycin-
A, 6 units of LDH and 5 units of PK and
pre warmed to 37uC
Buffers used for analysis of the activity of each complex of the ETC.
doi:10.1371/journal.pone.0012733.t002
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formaldehyde and 0.2% triton x100 for 20 minutes, again at 37uC.
Fixative was removed and again the cells were washed twice with
PBS prior to blocking in 1.1% BSA and 0.2% triton x100 for 30
minutes in the dark. Blocking solution was removed and replaced
with 1:100 dilution of sarcomeric a-actinin (ab9465, abcam) in
blocking buffer. Cells were incubated at 37uC for 2 hours.
Following incubation the primary antibody was removed and cells
were washed in PBS containing 0.2% triton x100. Following
washing cells were again incubated in blocking buffer for 30
minutes, before the addition of the secondary antibody (goat anti-
mouse Alexa fluor 488, cat# A11001, Invitrogen) diluted 1:500 in
blocking buffer for 1 hour at 37uC. Subsequently cells were washed
twice in PBS before image capture using an Imagexpress system
(Molecular Devices). Automated image analysis was conducted
using Metaexpress (Molecular Devices). Both the primary and
secondary antibody were incubated with cells alone to check for
cross reactivity.
Statistical and bioinformatic analysis
Microarray data was LOWESS normalized using ArrayTrack
(http://www.fda.gov/ScienceResearch/BioinformaticsTools/Array
track/default.htm) and pathway analysed using the Gene Set
Analysis Toolkit, KEGG pathway feature (http://bioinfo.vanderbilt.
edu/webgestalt). The significance of each KEGG pathway was
assessed using a modified Fisher exact test, this generates an
enrichment probability score (P value) [58]. All other data is express-
ed as the mean 6 SD of three to five independent experiments with
two technical replicates in each group. The data were analyzed using
one-way ANOVA, differences between individual means were
compared using a Dunnett’s post-hoc test. A probability of P#0.05
was used as the criterion for significance. The full dataset has been
submitted to GEO accession number GEO18459.
Supporting Information
Figure S1 Principal components analysis of the transcriptional
data for DOX and DMNQ.
Found at: doi:10.1371/journal.pone.0012733.s001 (4.33 MB EPS)
Figure S2 Activation of transcription factor NRF-1 with DOX
and DMNQ.
Found at: doi:10.1371/journal.pone.0012733.s002 (4.75 MB EPS)
Figure S3 Hierarchical clustering of genes regulated by NRF-1
with time after DOX (left) or DMNQ (right) treatment in vivo.
Found at: doi:10.1371/journal.pone.0012733.s003 (8.89 MB EPS)
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